Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 2Thoracic 1Plasma cell 1Other solid neoplasm 1Genitourinary 1

Conditions

Solid Tumors 1

Interventions

pembrolizumab 14Injections 13Pemetrexed 9Specimen Handling 8Carboplatin 8tislelizumab 7Interviews as Topic 7Cisplatin 7fludarabine 5atezolizumab 5Educational Status 5Cyclophosphamide 5Standard of Care 4Practice Guidelines as Topic 4Methods 4Fluorouracil 4Early Intervention, Educational 4Capecitabine 4Biopsy 4Bevacizumab 4Trastuzumab 3Platinum 3Paclitaxel 3Oxaliplatin 3Nivolumab 3Magnetic Resonance Spectroscopy 3Docetaxel 3Cetuximab 31,2-diaminocyclohexaneplatinum II citrate 3toripalimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
pegylated granulocyte colony-stimulating factor × Other solid neoplasm × 30 days × Clear all
NCT06926751 2026-05-07

Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting
132 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡